Sit Investment Associates’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-20,225
Closed -$748K 536
2023
Q4
$748K Sell
20,225
-23,700
-54% -$893K 0.02% 382
2023
Q3
$1.68M Sell
43,925
-9,850
-18% -$403K 0.05% 301
2023
Q2
$1.94M Hold
53,775
0.05% 290
2023
Q1
$2.05M Hold
53,775
0.06% 292
2022
Q4
$3.06M Hold
53,775
0.09% 245
2022
Q3
$2.13M Buy
53,775
+12,350
+30% +$546K 0.06% 268
2022
Q2
$1.82M Hold
41,425
0.06% 285
2022
Q1
$1.65M Hold
41,425
0.04% 313
2021
Q4
$1.67M Buy
+41,425
New +$1.55M 0.04% 330
2017
Q4
Sell
-68,000
Closed -$1.18M 644
2017
Q3
$1.18M Sell
68,000
-2,600
-4% -$35.2K 0.03% 337
2017
Q2
$905K Sell
70,600
-1,300
-2% -$17.4K 0.02% 359
2017
Q1
$932K Sell
71,900
-10,450
-13% -$132K 0.02% 364
2016
Q4
$814K Hold
82,350
0.02% 353
2016
Q3
$995K Hold
82,350
0.03% 304
2016
Q2
$711K Hold
82,350
0.02% 336
2016
Q1
$780K Hold
82,350
0.01% 339
2015
Q4
$1.43M Hold
82,350
0.03% 282
2015
Q3
$1.11M Hold
82,350
0.02% 303
2015
Q2
$1.86M Sell
82,350
-35,900
-30% -$631K 0.03% 251
2015
Q1
$1.69M Buy
118,250
+62,350
+112% +$899K 0.03% 257
2014
Q4
$539K Buy
+55,900
New +$497K 0.01% 352

Other funds holding HALO

Sit Investment Associates's HALO Position: Q1 2024 in Review

Sit Investment Associates sold out of Halozyme (HALO) in Q1 2024, closing a stake of 20,225 shares — an estimated $748K sold.

Sit Investment Associates first reported a position in HALO in Q4 2014 and held it in 21 quarters. The position peaked at $3.06M in Q4 2022. 414 funds tracked by Wall St. Rank hold HALO as of Q1 2024.

  • Sit Investment Associates reported no remaining Halozyme position as of Q1 2024 after selling out during the quarter.
  • Sit Investment Associates sold 20,225 Halozyme shares in Q1 2024, an estimated $748K.
  • Sit Investment Associates first reported a position in Halozyme in Q4 2014 and held it in 21 quarters.
  • Sit Investment Associates's Halozyme position peaked at $3.06M in Q4 2022.
  • 414 funds tracked by Wall St. Rank held Halozyme as of Q1 2024.

Based on Sit Investment Associates's 13F filing for Q1 2024, filed 14 May 2024.